In melanoma, activating mutations in CDK4 abolish interactions with the tumor suppressor Cyclin dependent kinase inhibitor 2 A’s (CDKN2A) / p16INK4A, rendering the protein constitutively active, leading to uncontrolled cell cycling [62]. Here, CDKN2A is linked to melanoma.